Novo Nordisk shares plunged nearly 20–23% on July 29, 2025, marking its worst trading day since Black Monday in 1987.
Significant Downgrade of 2025 Financial Outlook
The company revised its sales growth forecast for 2025 down to 8–14%, from its prior guidance of 13–21%, and reduced expected operating profit growth from 16–24% to 10–16%. This adjustment was attributed to weaker-than-expected demand for Wegovy and Ozempic, and rising competitive pressures
#TheWallStreetJournal
I will start my accumulation using DCA, but will be happier to start buying this stock heavily from $47 zone.
trade with care.
I look forward to connecting with you
Significant Downgrade of 2025 Financial Outlook
The company revised its sales growth forecast for 2025 down to 8–14%, from its prior guidance of 13–21%, and reduced expected operating profit growth from 16–24% to 10–16%. This adjustment was attributed to weaker-than-expected demand for Wegovy and Ozempic, and rising competitive pressures
#TheWallStreetJournal
I will start my accumulation using DCA, but will be happier to start buying this stock heavily from $47 zone.
trade with care.
I look forward to connecting with you
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.